Have safety and efficacy assessments of bioactives come of age?
Authors
Johanna DSc,RD
Office of Dietary Supplements, National Institutes of Health, 6705 Rockledge Drive, Bethesda, MD, 20892; U.S. Department of Agriculture, Jean Mayer Human Nutrition Research Center on Aging, Tufts University, Boston, MA, 02111
This article describes why the safety and efficacy assessment of non-nutrient bioactives for reducing chronic disease risk is so complicated, especially for dietary supplements and traditional medicines. Scientists, regulators, and the public have different and sometimes opposing perspectives about bioactives. Drug, food, and traditional medicine models used for bioactive safety assessment are based on different assumptions and use different processes. Efficacy assessment is seldom based on clinical trials of boactives’ effects in reducing chronic disease risk. It usually consists of application of quality assurance measures and evaluation of label claims and commercial speech about ingredients or products to ensure conformity to regulations. Harmonization of safety and efficacy assessment on a global basis is difficult because of differences within and between regulatory systems. The recommendations provided may open the way for bioactives to play a larger health role in the future, fill gaps in data needed for crafting authoritative dietary guidance on intakes, and speed harmonization of global standards.
Keywords: Bioactives, Nutraceuticals, Functional ingredients, Safety, Effectiveness, Dietary Recommendations, Regulation, Policy
Click on "Archives" to access the full archive of scientific preprints. You may use the categories and the search functionality to find select preprints you're interested in.
